摘要
轻微肝性脑病(MHE)是指肝硬化患者出现神经心理学/神经生理学异常但认知功能正常的一种状态,在肝硬化患者中常见。早期诊断治疗MHE,可提高患者生活质量,减少意外死亡。目前主要通过心理测量肝性脑病评分诊断MHE,但其操作繁琐耗时,受年龄与教育水平等影响,临床诊断可靠性欠佳。血清生物标志物作为客观的参考指标,检测操作简便,临床容易推广。S100β、3-硝基酪氨酸、动脉血氨等潜在血清生物学标志物的特异度、敏感度及诊断价值各有优劣。现就上述血清生物学标志物进行了综述。
Minimal hepatic encephalopathy(MHE)refers to a state of neuropsychological or neurophysiological abnormality and normal cognitive function in patients with liver cirrhosis,which is commonly seen in patients with liver cirrhosis.Early diagnosis and treatment of MHE can improve the quality of life of patients and reduce accidental deaths.At present,Psychometric Hepatic Encephalopathy Score is mainly used for the diagnosis of MHE,but its operation is complicated and time-consuming and is affected by age and educational level,with unsatisfactory reliability in clinical diagnosis.Serum biomarkers are objective reference indicators with simple and convenient measurement and can easily be promoted in clinical practice.Potential serum biomarkers such as S100β,3-nitrotyrosine,and arterial blood ammonia have their own advantages and disadvantages in specificity,sensitivity,and diagnostic value.This article reviews the above-mentioned serum biomarkers.
作者
张钦富
韩焕钦
郑伟强
ZHANG Qinfu;HAN Huanqin;ZHENG Weiqiang(Infectious Diseases Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2020年第12期2819-2821,共3页
Journal of Clinical Hepatology
基金
广东省医学科学技术研究基金项目(A2017455)。
关键词
肝性脑病
生物标记
诊断
hepatic encephalopathy
biomarkers
diagnosis